Clinical trials: Clopidogrel, completed
Coronary Disease
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
- Trial name
- NCT00140465
- Testing
- Clopidogrel
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Ischemia
The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment
To investigate if treatment with ticagrelor can mitigate the transient loss of endothelium-dependent vasodilatation of the resistance vasculature following a short period of ischemia, compared with clopidogrel at standard…
- Trial name
- NCT02580149
- Testing
- Ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Michael Wolzt, Prof. MD
Cardiac Dysfunction
Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
Extracorporeal membrane oxygenation (ECMO) is the device which increases the supply of oxygen to the body tissues in vitro and to assist in heart and lung function.
- Trial name
- NCT02581280
- Testing
- Residual blood
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Myocardial Ischemia
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
The new P2Y12 inhibitors prasugrel (Efient®-Effient®) and ticagrelor (Brilique®-Brilinta®) have shown promising results in the respective TRITON and PLATO trials making of prasugrel and ticagrelor recommended first line…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Stent Thrombosis
- Trial name
- ALPHEUS (NCT02617290)
- Testing
- Ticagrelor, Clopidogrel
- Where
- France
- Volunteers
- 1,900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteers
Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin.
- Trial name
- NCT00152724
- Testing
- pressure strain system, iontophoresis, scopolamin, emla
- Where
- France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Myocardial Infarction
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)
Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration…
- Trial name
- SCORE (NCT00781573)
- Testing
- Clopidogrel
- Where
- 3 sites in United States, Greece and 1 more
- Volunteers
- 167 people
- Sponsor
- North Texas Veterans Healthcare System
Acute Ischemic Stroke
Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)
Stroke is a common cause of disability. The most common type of stroke, an ischemic stroke, is caused by a blood vessel in the brain getting blocked by a clot.
- Trial name
- CoPrime (NCT06638151)
- Testing
- aspirin + clopidogrel, Aspirin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of Alberta
Coronary Artery Disease
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
It is not uncommon that patients requiring dual antiplatelet therapy (DAPT) also need to be treated with oral anticoagulant therapy, such as those with atrial fibrillation (AF).
- Trial name
- EDOX-APT (NCT02567461)
- Testing
- Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Florida
Coronary Artery Disease
Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
This is randomized-controlled trial to evaluate the difference of composite of cardiac death, myocardial infarction, or Stroke between the dual antiplatelet therapy group and the aspirin monotherapy group after 1-year of…
- Trial name
- DES-LATE (NCT01186146)
- Testing
- Aspirin monotherapy, Aspirin,Clopidogrel
- Where
- 19 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Seung-Jung Park
Chronic Kidney Disease
The Canadian Prevention of Renal and Cardiovascular Endpoints Trial
Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat.
- Trial name
- CanPrevent (NCT00231803)
- Testing
- Combined CKD and CVD Prevention, Cardiovascular Disease prevention, Treatment of Chronic Kidney Disease complications
- Where
- 5 sites in Canada
- Volunteers
- 474 people
- Sponsor
- Brendan Barrett
Cerebral Infarction
Chinese Assessment for Vinpocetine In Neurology
Trial Title：The treatment of Vinpocetine（Cavinton）in patients with cerebral infarction, an open, randomized, multi-center control study 1.
- Trial name
- CAVIN (NCT01400035)
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Shanghai Rxmidas Pharmaceuticals Co. Ltd.
Coronary Artery Disease, Myocardial Infarction
Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis
The primary objective of this study is to establish a cut off level of platelet inhibition that separates patients with or without previous stent occlusion with acute clinical onset while on aspirin and clopidogrel treatment…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Stent Thrombosis, Heart Diseases
- Trial name
- TOPAS-1 (NCT00914368)
- Testing
- Clopidogrel
- Where
- Sweden
- Volunteers
- 450 people
- Sponsor
- Uppsala University
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
- Trial name
- NCT01523366
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Stent Thrombosis, Clopidogrel
VerifyNow French Registry
The purpose of this study is to determine the effect of clopidogrel or aspirin reactivity as measured by a point-of-care platelet function assay on thrombotic or bleeding events after percutaneous coronary intervention (PCI) with…
- Conditions
- Stent Thrombosis, Clopidogrel, Aspirin, Bleeding
- Trial name
- VERIFRENCHY (NCT00753753)
- Where
- France
- Volunteers
- 1,001 people
- Sponsor
- Association Pour le Développement des Soins Cardiologiques de la ville de Chartres
Atrial Fibrillation, Atrial Appendage
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure.
- Conditions
- Atrial Fibrillation, Atrial Appendage, Hemorrhage
- Trial name
- ADRIFT (NCT03273322)
- Testing
- Rivaroxaban 10 mg qd, Rivaroxaban 15 mg qd, DAPT
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
Prospective, multicenter, randomized (two-arm 1:1), non-inferiority clinical evaluation comparing 2 regimes of dual antiplatelet therapy (DAPT) with aspirin + clopidogrel following percutaneous coronary intervention (PCI) with…
- Trial name
- OPTIMIZE (NCT01113372)
- Testing
- Clopidogrel
- Where
- 32 sites in Brazil
- Volunteers
- 3,119 people
- Sponsor
- Cardiovascular Research Center, Brazil
Cerebrovascular Occlusion, Collateral Blood Circulation
The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion
Stroke is the first leading cause of death in China, and is responsible for almost 22.4% of deaths. In approximately 80% of cases stroke is ischaemic, i.e.
- Conditions
- Cerebrovascular Occlusion, Collateral Blood Circulation, Anterior Cerebral Circulation Infarction
- Trial name
- INCIMO (NCT02594995)
- Testing
- NBP
- Where
- China
- Volunteers
- 311 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
COVID-19, Venous Thromboembolism
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
The researchers wanted to learn how to help sick patients who are in the hospital because of COVID-19. They are trying to find out the best way that is safe to stop blood clots that could be dangerous from forming in patients…
- Conditions
- COVID-19, Venous Thromboembolism, Arterial Thrombosis
- Trial name
- COVID-PACT (NCT04409834)
- Testing
- Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- The TIMI Study Group
Acute Coronary Syndrome
Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
The purpose of this study is to demonstrate the superiority of a strategy of platelet monitoring (Monitoring Arm) with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low…
- Trial name
- ANTARCTIC (NCT01538446)
- Testing
- Modification of Prasugrel based on a biological assay, prasugrel / clopidogrel, Verify Now
- Where
- 2 sites in France
- Volunteers
- 880 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris